Free tool
FAERS Monitor: Elmiron
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020193 or its brand name (Elmiron, Pentosan Polysulfate Sodium). Reports on generic versions are filed under their own applications.
Reports
6,930
Serious
4,861
70% of reports
Hospitalization
653
Death reported
120
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,404
- maculopathy1,398
- retinal pigmentation607
- dry age-related macular degeneration562
- pigmentary maculopathy470
- drug ineffective354
- pain304
- nausea278
- product use issue272
- headache237
- cystitis interstitial214
- macular degeneration214
- diarrhoea208
- alopecia206
- fatigue199
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 41 |
| 2005 | 51 |
| 2006 | 57 |
| 2007 | 52 |
| 2008 | 69 |
| 2009 | 70 |
| 2010 | 112 |
| 2011 | 169 |
| 2012 | 157 |
| 2013 | 146 |
| 2014 | 170 |
| 2015 | 565 |
| 2016 | 355 |
| 2017 | 276 |
| 2018 | 331 |
| 2019 | 334 |
| 2020 | 499 |
| 2021 | 686 |
| 2022 | 1,541 |
| 2023 | 601 |
| 2024 | 331 |
| 2025 | 223 |
| 2026 | 94 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,229 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pigmentary maculopathySignal | 470 | 118953.8 | 67103.7 | 1,388,955 |
| retinal pigmentationSignal | 607 | 10185.3 | 8642.0 | 1,417,515 |
| dry age-related macular degenerationSignal | 562 | 3114.7 | 2775.5 | 862,148 |
| maculopathySignal | 1,398 | 1972.1 | 1851.5 | 1,668,964 |
| cystitis interstitialSignal | 214 | 465.6 | 404.0 | 85,623 |
| macular degenerationSignal | 214 | 55.4 | 48.5 | 11,170 |
| off label useSignal | 1,404 | 4.9 | 4.7 | 4,498 |
| product use issueSignal | 272 | 4.4 | 3.9 | 716 |
| alopeciaSignal | 206 | 3.2 | 2.8 | 309 |
| pain | 304 | 1.5 | 1.3 | 52 |
| headache | 237 | 1.1 | 1.0 | 4 |
| nausea | 278 | 1.1 | 1.0 | 1 |
| diarrhoea | 208 | 1.0 | 0.9 | 0 |
| drug ineffective | 354 | 0.8 | 0.7 | 16 |
| fatigue | 199 | 0.8 | 0.7 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.